Nanjing Jiangyuan Andico Positron Research and Development

Nanjing Jiangyuan Andico Positron Research and Development is a leading Chinese radiopharmaceutical company specializing in the development, production, and distribution of positron emission tomography (PET) tracers. The company operates an extensive network of radiopharmacies across China, providing essential diagnostic agents such as Fluorodeoxyglucose (18F-FDG) and Florbetapir (18F) for oncology and neurology. Following its acquisition by China Isotope & Radiation Corporation (CIRC), Andico has strengthened its position in the molecular imaging market through strategic partnerships and a robust pipeline of diagnostic and therapeutic radiopharmaceuticals. Their core business focuses on expanding access to advanced medical imaging technologies for early disease detection and personalized medicine.